Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey

Acta Obstet Gynecol Scand. 2012 Aug;91(8):976-82. doi: 10.1111/j.1600-0412.2012.01438.x. Epub 2012 Jun 18.

Abstract

Objective: To present Danish national survival data on women with early stage endometrial cancer and use these data to discuss the relevance of postoperative follow-up.

Design: Prospective study.

Setting: Danish Endometrial Cancer Study (DEMCA).

Population: Five hundred and seventy-one FIGO stage IA (1988 classification) endometrial cancer patients prospectively included between 1986 and 1999. All patients had total abdominal hysterectomy and bilateral salpingo-oophorectomy without adjuvant therapy.

Methods: The patient and the disease characteristics were drawn from the DEMCA database with cross-references to the national death registry and the national pathology database. Statistical methods included Kaplan-Meier, log-rank and Cox regression analysis.

Main outcome measures: Survival rates in relation to histopathology.

Results: The five year overall survival rate was 88.9% and five year disease-specific survival was 97.3%. Patients with low- (91.8%) and high-risk histopathology (8.2%) were compared. The age-adjusted overall and disease-specific survival differed significantly between women with low- and high-risk histopathology (p = 0.039 and p = 0.004, respectively). The disease-specific survival adjusted for age between patients with well-differentiated endometrioid tumors differed from those with moderately differentiated tumors (p = 0.008, hazard ratio = 3.75, 95% confidence interval 1.41-10.00). Recurrence data were available on 464 patients. Twenty-three (3.9%) experienced recurrence. Of these recurrences, 15 of 23 (65%) were vaginal. Death from recurrence was observed in nine of 23 (39%) patients, and five of these nine had vaginal recurrences.

Conclusions: Women with FIGO stage IA endometrial cancer have a very high disease-specific five year survival. Survival was related to histopathology. Follow-up at a highly specialized tertiary care center for patients with an extremely good prognosis may be questioned.

Publication types

  • Multicenter Study

MeSH terms

  • Adenocarcinoma / mortality*
  • Adenocarcinoma / pathology*
  • Adenocarcinoma / surgery
  • Adenocarcinoma, Clear Cell / mortality
  • Adenocarcinoma, Clear Cell / pathology
  • Adenocarcinoma, Mucinous / mortality
  • Adenocarcinoma, Mucinous / pathology
  • Adult
  • Aged
  • Carcinoma, Adenosquamous / mortality
  • Carcinoma, Adenosquamous / pathology
  • Carcinoma, Endometrioid / mortality
  • Carcinoma, Endometrioid / pathology
  • Cystadenocarcinoma, Serous / mortality
  • Cystadenocarcinoma, Serous / pathology
  • Databases, Factual
  • Denmark / epidemiology
  • Endometrial Neoplasms / mortality*
  • Endometrial Neoplasms / pathology*
  • Endometrial Neoplasms / surgery
  • Female
  • Follow-Up Studies
  • Humans
  • Hysterectomy*
  • Kaplan-Meier Estimate
  • Middle Aged
  • Neoplasm Staging
  • Odds Ratio
  • Ovariectomy*
  • Prognosis
  • Proportional Hazards Models
  • Prospective Studies
  • Recurrence
  • Registries
  • Risk Factors
  • Salpingectomy*
  • Survival Rate
  • Treatment Outcome